Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial.

@article{Grant2010InfliximabTF,
  title={Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial.},
  author={Annika Grant and Tayler Gonzalez and Michael O Montgomery and Vanessa C{\'a}rdenas and Francisco A. Kerdel},
  journal={Journal of the American Academy of Dermatology},
  year={2010},
  volume={62 2},
  pages={205-17}
}
BACKGROUND Biologic therapies with anti-tumor necrosis factor agents are promising treatments for hidradenitis suppurativa (HS). OBJECTIVE We assessed the efficacy and safety of infliximab (IFX) for the treatment of moderate to severe HS. METHODS A prospective double-blind treatment phase of 8 weeks where patients received IFX or placebo was followed by an open-label phase where patients taking placebo were given the opportunity to cross over to IFX, and an observational phase. Primary… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 87 extracted citations

Similar Papers

Loading similar papers…